Format

Send to

Choose Destination
See comment in PubMed Commons below
Can J Urol. 2006 Apr;13 Suppl 2:63-7.

Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy.

Author information

  • 1Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada.

Abstract

Risk categorization based on pre-treatment PSA, clinical stage and Gleason score is now widely used in the management of patients with localized prostate cancer. In patients with low-risk disease (cT1-T2a, PSA < 10 ng/ml and Gleason score < 6) there is no role for the routine use of adjunctive hormonal therapy. In intermediate-risk patients (T1-T2, PSA < 20 ng/ml and Gleason <or= 7) there is some evidence to suggest improved outcomes with neo-adjuvant hormonal therapy when low-dose external beam radiation therapy (EBRT) is used. However, with appropriate modern dose EBRT there is little data to support the use of routine adjunctive hormonal therapy and this should be done only in the context of a clinical trial.

PMID:
16672132
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk